{'52WeekChange': -0.2823891,
 'SandP52WeekChange': None,
 'address1': '331 Treble Cove Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 15.83,
 'askSize': 1300,
 'averageDailyVolume10Day': 592887,
 'averageVolume': 656101,
 'averageVolume10days': 592887,
 'beta': 1.240336,
 'beta3Year': None,
 'bid': 15.8,
 'bidSize': 1800,
 'bookValue': 2.979,
 'category': None,
 'circulatingSupply': None,
 'city': 'North Billerica',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 16.47,
 'dayLow': 15.56,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': -0.665,
 'enterpriseToEbitda': 11.385,
 'enterpriseToRevenue': 2.062,
 'enterpriseValue': 725000960,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 14.549,
 'fiftyTwoWeekHigh': 27.12,
 'fiftyTwoWeekLow': 8.67,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 39000993,
 'forwardEps': 1.19,
 'forwardPE': 13.268907,
 'fromCurrency': None,
 'fullTimeEmployees': 508,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.04168,
 'heldPercentInstitutions': 1.0579901,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/lantheus.com',
 'longBusinessSummary': 'Lantheus Holdings, Inc. develops, manufactures, and '
                        'commercializes diagnostic medical imaging agents and '
                        'products that assist clinicians in the diagnosis and '
                        'treatment of cardiovascular and other diseases '
                        'worldwide. Its principal products include DEFINITY, a '
                        'microbubble contrast agent used in ultrasound exams '
                        'of the heart; and TechneLite, a technetium generator '
                        'that provides the nuclear material used in nuclear '
                        'medicine procedures. The company also offers Xenon, a '
                        'radiopharmaceutical gas used to assess pulmonary '
                        'function, and to image cerebral blood flow; '
                        'Neurolite, an injectable to identify the area within '
                        'the brain where blood flow has been blocked or '
                        'reduced due to stroke; Cardiolite, an injectable '
                        'technetium-labeled imaging agent used in myocardial '
                        'perfusion imaging (MPI) procedures; FDG, a '
                        'fluorine-18-radiolabeled imaging agent to identify '
                        'and characterize tumors in patients undergoing '
                        'oncologic diagnostic procedures; and Cobalt (Co 57), '
                        'a non-pharmaceutical radiochemical. In addition, it '
                        'provides injectable radiopharmaceutical imaging '
                        'agents, such as Thallium TI 201, which is used in MPI '
                        'studies to detect cardiovascular disease; Gallium Ga '
                        '67 that is used to detect various infections and '
                        'cancerous tumors; and Quadramet, a therapeutic '
                        'product, which is used to treat severe bone pain '
                        'associated with metastatic bone lesions. Further, the '
                        'company is developing Flurpiridaz F 18, which is in '
                        'Phase III clinical trials to assess blood flow to the '
                        'heart; and LMI 1195 that is in Phase III clinical '
                        'trials for the diagnosis and treatment follow-up of '
                        'neuroendocrine tumors. It sells its products to '
                        'radiopharmacies, integrated delivery networks, '
                        'hospitals, clinics, and group practices. The company '
                        'has a strategic collaboration and license agreement '
                        'with NanoMab Technology Limited to provide an imaging '
                        'biomarker research tool to pharmaceutical companies '
                        'and academic centers conducting research and '
                        'development on PD-L1 immuno-oncology treatments. The '
                        'company was founded in 1956 and is headquartered in '
                        'North Billerica, Massachusetts.',
 'longName': 'Lantheus Holdings, Inc.',
 'market': 'us_market',
 'marketCap': 1054549376,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_8285048',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 25055000,
 'nextFiscalYearEnd': 1640908800,
 'open': 16.22,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 1.66,
 'phone': '978 671 8001',
 'previousClose': 16.34,
 'priceHint': 2,
 'priceToBook': 5.300436,
 'priceToSalesTrailing12Months': 2.9998758,
 'profitMargins': 0.07127,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 16.47,
 'regularMarketDayLow': 15.56,
 'regularMarketOpen': 16.22,
 'regularMarketPreviousClose': 16.34,
 'regularMarketPrice': 16.22,
 'regularMarketVolume': 427168,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39941000,
 'sharesPercentSharesOut': 0.0476,
 'sharesShort': 3177824,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2168792,
 'shortName': 'Lantheus Holdings, Inc.',
 'shortPercentOfFloat': 0.053000003,
 'shortRatio': 3.12,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'LNTH',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.621,
 'trailingPE': 25.426731,
 'twoHundredDayAverage': 14.547518,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'e854c3fb-8328-3f4c-9161-58b3c91379f7',
 'volume': 427168,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.lantheus.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '01862'}